ClearFlow, Inc. has announced that its PleuraFlow Active Clearance Technology, known as ACT, has received an Innovative Technology contract from Vizient, the largest provider-driven healthcare performance improvement company in the United States. The contract was granted after a thorough evaluation by hospital experts serving on one of Vizient’s client-led councils. This recognition highlights PleuraFlow ACT’s unique ability to enhance patient care and support better clinical outcomes, signaling to Vizient clients that the technology offers significant value for postoperative care.
Health Technology Insights: Steven Gonzalez on Leadership Presence and Future of Work
Vizient’s Innovative Technology contracts are awarded to products that have been reviewed and tested through the company’s Innovative Technology Program. These products are assessed by client-led councils, which identify technologies that could improve clinical care, enhance patient and healthcare worker safety, or boost operational efficiency for healthcare organizations. The award indicates that PleuraFlow ACT met these criteria and demonstrated a meaningful contribution to healthcare delivery.
Hannah Beathard, CEO of ClearFlow, emphasized the importance of this recognition for the company, stating that the award underscores the growing awareness of the impact of chest tube occlusion on postoperative complications. She noted that PleuraFlow ACT provides both clinical and economic benefits and expressed the company’s commitment to working with Vizient clients to support safer, more effective recovery following cardiothoracic surgery.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 3 February 2026
PleuraFlow ACT is an FDA-cleared chest drainage system designed to proactively maintain chest tube patency after surgery. Unlike traditional chest tubes, which often become blocked by clots in areas that are difficult for clinicians to monitor, PleuraFlow ACT uses a proprietary active clearance mechanism to remove intraluminal clots while keeping the system closed and sterile. Clinical studies have shown that PleuraFlow improves fluid drainage, reduces complications associated with retained blood, and supports faster and safer patient recovery.
Kelly Flaharty, Associate Vice President of Contract Operations at Vizient, stated that after reviewing PleuraFlow ACT, the client-led council concluded that the technology offers a unique advantage over other available products. The council recommended it for the Innovative Technology contract, reflecting its potential to improve patient care in hospitals and surgical centers.
Vizient’s client base includes academic medical centers, community hospitals, pediatric facilities, integrated delivery networks, and non-acute care providers, representing over $156 billion in annual purchasing volume. The Innovative Technology Program allows Vizient to work closely with councils and task forces to evaluate new products and identify those that bring genuine innovation to healthcare. ClearFlow’s recognition through this program positions PleuraFlow ACT as a leading solution for enhancing postoperative outcomes and advancing the standard of care in cardiothoracic surgery.
Health Technology Insights: TransLogic Launches Secure Tube System Monitoring
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
